On Monday, KalVista Pharmaceuticals Inc (NASDAQ: KALV) was 9.10% up from the session before settling in for the closing price of $13.62. A 52-week range for KALV has been $7.30 – $17.28.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -17.63%. When this article was written, the company’s average yearly earnings per share was at 87.71%. With a float of $37.91 million, this company’s outstanding shares have now reached $50.34 million.
KalVista Pharmaceuticals Inc (KALV) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward KalVista Pharmaceuticals Inc stocks. The insider ownership of KalVista Pharmaceuticals Inc is 25.00%, while institutional ownership is 97.68%. The most recent insider transaction that took place on Nov 12 ’25, was worth 38,438. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 3,328 shares at a rate of $11.55, taking the stock ownership to the 398,981 shares. Before that another transaction happened on Sep 08 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 7,294 for $15.84, making the entire transaction worth $115,537. This insider now owns 395,189 shares in total.
KalVista Pharmaceuticals Inc (KALV) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 4/30/2024, it has been observed that the corporation posted -1.07 earnings per share (EPS) during the time that was less than consensus figure (set at -0.72) by -0.35. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
You can see what KalVista Pharmaceuticals Inc (KALV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 525.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.00 and is forecasted to reach 0.91 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Compared to the last year’s volume of 0.92 million, its volume of 2.39 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 92.94%.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 64.77%, which indicates a significant decrease from 97.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.75 in the past 14 days, which was higher than the 0.74 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.15, while its 200-day Moving Average is $12.39. Nevertheless, the first resistance level for the watch stands at $15.45 in the near term. At $16.03, the stock is likely to face the second major resistance level. The third major resistance level sits at $17.10. If the price goes on to break the first support level at $13.80, it is likely to go to the next support level at $12.73. Now, if the price goes above the second support level, the third support stands at $12.15.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
There are 50,546K outstanding shares of the company, which has a market capitalization of 751.12 million. As of now, sales total 0 K while income totals -183,440 K. Its latest quarter income was 1,430 K while its last quarter net income were -60,100 K.
